ASX - By Stock
|
PAA |
Re:
PAA TOP HOLDERS MOVEMENTS AS AT 30 APRIL 2024
|
|
adreamer
|
20 |
8.2K |
0 |
04/08/24 |
04/08/24 |
ASX - By Stock
|
20
|
8.2K
|
0
|
|
ASX - By Stock
|
PAA |
Re:
Pharmaust - Media & News
|
|
adreamer
|
121 |
43K |
32 |
25/07/24 |
25/07/24 |
ASX - By Stock
|
121
|
43K
|
32
|
|
ASX - By Stock
|
PAA Algorithmic Trading |
Re:
Stop the rort
|
|
adreamer
|
2 |
1.5K |
19 |
25/07/24 |
25/07/24 |
ASX - By Stock
|
2
|
1.5K
|
19
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust Completes Share Purchase Plan
|
|
adreamer
|
107 |
27K |
46 |
24/07/24 |
24/07/24 |
ASX - By Stock
|
107
|
27K
|
46
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
adreamer
|
978 |
267K |
19 |
20/07/24 |
20/07/24 |
ASX - By Stock
|
978
|
267K
|
19
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
adreamer
|
978 |
267K |
9 |
19/07/24 |
19/07/24 |
ASX - By Stock
|
978
|
267K
|
9
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
adreamer
|
978 |
267K |
17 |
19/07/24 |
19/07/24 |
ASX - By Stock
|
978
|
267K
|
17
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
adreamer
|
978 |
267K |
35 |
19/07/24 |
19/07/24 |
ASX - By Stock
|
978
|
267K
|
35
|
|
ASX - By Stock
|
PAA Biotech |
Company Analysis - Morgans
|
|
adreamer
|
19 |
8.4K |
54 |
04/07/24 |
04/07/24 |
ASX - By Stock
|
19
|
8.4K
|
54
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
adreamer
|
159 |
41K |
8 |
20/06/24 |
20/06/24 |
ASX - By Stock
|
159
|
41K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
adreamer
|
159 |
41K |
5 |
20/06/24 |
20/06/24 |
ASX - By Stock
|
159
|
41K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
adreamer
|
159 |
41K |
2 |
20/06/24 |
20/06/24 |
ASX - By Stock
|
159
|
41K
|
2
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
adreamer
|
159 |
41K |
4 |
20/06/24 |
20/06/24 |
ASX - By Stock
|
159
|
41K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
adreamer
|
159 |
41K |
6 |
20/06/24 |
20/06/24 |
ASX - By Stock
|
159
|
41K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
adreamer
|
159 |
41K |
7 |
20/06/24 |
20/06/24 |
ASX - By Stock
|
159
|
41K
|
7
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
adreamer
|
159 |
41K |
5 |
20/06/24 |
20/06/24 |
ASX - By Stock
|
159
|
41K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
adreamer
|
159 |
41K |
7 |
20/06/24 |
20/06/24 |
ASX - By Stock
|
159
|
41K
|
7
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
adreamer
|
159 |
41K |
11 |
19/06/24 |
19/06/24 |
ASX - By Stock
|
159
|
41K
|
11
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
adreamer
|
159 |
41K |
23 |
19/06/24 |
19/06/24 |
ASX - By Stock
|
159
|
41K
|
23
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
adreamer
|
159 |
41K |
13 |
19/06/24 |
19/06/24 |
ASX - By Stock
|
159
|
41K
|
13
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
adreamer
|
159 |
41K |
5 |
19/06/24 |
19/06/24 |
ASX - By Stock
|
159
|
41K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
adreamer
|
159 |
41K |
9 |
19/06/24 |
19/06/24 |
ASX - By Stock
|
159
|
41K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
adreamer
|
159 |
41K |
14 |
19/06/24 |
19/06/24 |
ASX - By Stock
|
159
|
41K
|
14
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
adreamer
|
159 |
41K |
9 |
19/06/24 |
19/06/24 |
ASX - By Stock
|
159
|
41K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
adreamer
|
159 |
41K |
9 |
19/06/24 |
19/06/24 |
ASX - By Stock
|
159
|
41K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
adreamer
|
159 |
41K |
23 |
19/06/24 |
19/06/24 |
ASX - By Stock
|
159
|
41K
|
23
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
adreamer
|
159 |
41K |
23 |
19/06/24 |
19/06/24 |
ASX - By Stock
|
159
|
41K
|
23
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
adreamer
|
159 |
41K |
11 |
19/06/24 |
19/06/24 |
ASX - By Stock
|
159
|
41K
|
11
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Appointment of Non-Executive Director
|
|
adreamer
|
45 |
11K |
34 |
18/06/24 |
18/06/24 |
ASX - By Stock
|
45
|
11K
|
34
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Appointment of Non-Executive Director
|
|
adreamer
|
45 |
11K |
27 |
17/06/24 |
17/06/24 |
ASX - By Stock
|
45
|
11K
|
27
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Appointment of Non-Executive Director
|
|
adreamer
|
45 |
11K |
21 |
17/06/24 |
17/06/24 |
ASX - By Stock
|
45
|
11K
|
21
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Appointment of Non-Executive Director
|
|
adreamer
|
45 |
11K |
36 |
17/06/24 |
17/06/24 |
ASX - By Stock
|
45
|
11K
|
36
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Appointment of Non-Executive Director
|
|
adreamer
|
45 |
11K |
28 |
17/06/24 |
17/06/24 |
ASX - By Stock
|
45
|
11K
|
28
|
|
ASX - By Stock
|
PAA |
Re:
Pharmaust - Media & News
|
|
adreamer
|
121 |
43K |
40 |
16/06/24 |
16/06/24 |
ASX - By Stock
|
121
|
43K
|
40
|
|
ASX - By Stock
|
PAA |
Re:
Pharmaust - Media & News
|
|
adreamer
|
121 |
43K |
7 |
16/06/24 |
16/06/24 |
ASX - By Stock
|
121
|
43K
|
7
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
adreamer
|
248 |
68K |
12 |
15/06/24 |
15/06/24 |
ASX - By Stock
|
248
|
68K
|
12
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
adreamer
|
248 |
68K |
9 |
14/06/24 |
14/06/24 |
ASX - By Stock
|
248
|
68K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
adreamer
|
248 |
68K |
9 |
14/06/24 |
14/06/24 |
ASX - By Stock
|
248
|
68K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
adreamer
|
248 |
68K |
21 |
14/06/24 |
14/06/24 |
ASX - By Stock
|
248
|
68K
|
21
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
adreamer
|
248 |
68K |
18 |
13/06/24 |
13/06/24 |
ASX - By Stock
|
248
|
68K
|
18
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
adreamer
|
248 |
68K |
4 |
12/06/24 |
12/06/24 |
ASX - By Stock
|
248
|
68K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
adreamer
|
248 |
68K |
9 |
12/06/24 |
12/06/24 |
ASX - By Stock
|
248
|
68K
|
9
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
adreamer
|
978 |
267K |
13 |
12/06/24 |
12/06/24 |
ASX - By Stock
|
978
|
267K
|
13
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
adreamer
|
978 |
267K |
18 |
12/06/24 |
12/06/24 |
ASX - By Stock
|
978
|
267K
|
18
|
|
ASX - By Stock
|
PAA |
Re:
STRIKE Trial - Phase 2 / 3 - The final frontier to commercial outcome
|
|
adreamer
|
49 |
11K |
10 |
12/06/24 |
12/06/24 |
ASX - By Stock
|
49
|
11K
|
10
|
|
ASX - By Stock
|
PAA Biotech |
Re:
BIG FREEZE - CHILLS AND THRILLS
|
|
adreamer
|
58 |
14K |
3 |
11/06/24 |
11/06/24 |
ASX - By Stock
|
58
|
14K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
STRIKE Trial - Phase 2 / 3 - The final frontier to commercial outcome
|
|
adreamer
|
49 |
11K |
4 |
11/06/24 |
11/06/24 |
ASX - By Stock
|
49
|
11K
|
4
|
|
ASX - By Stock
|
PAA Biotech |
Re:
BIG FREEZE - CHILLS AND THRILLS
|
|
adreamer
|
58 |
14K |
27 |
11/06/24 |
11/06/24 |
ASX - By Stock
|
58
|
14K
|
27
|
|
ASX - By Stock
|
PAA Biotech |
Re:
BIG FREEZE - CHILLS AND THRILLS
|
|
adreamer
|
58 |
14K |
4 |
11/06/24 |
11/06/24 |
ASX - By Stock
|
58
|
14K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
STRIKE Trial - Phase 2 / 3 - The final frontier to commercial outcome
|
|
adreamer
|
49 |
11K |
7 |
11/06/24 |
11/06/24 |
ASX - By Stock
|
49
|
11K
|
7
|
|